DK1556058T3 - Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi - Google Patents

Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi

Info

Publication number
DK1556058T3
DK1556058T3 DK03759076T DK03759076T DK1556058T3 DK 1556058 T3 DK1556058 T3 DK 1556058T3 DK 03759076 T DK03759076 T DK 03759076T DK 03759076 T DK03759076 T DK 03759076T DK 1556058 T3 DK1556058 T3 DK 1556058T3
Authority
DK
Denmark
Prior art keywords
oestetrol
derivatives
pharmaceutical compositions
cancer therapy
estrogen
Prior art date
Application number
DK03759076T
Other languages
English (en)
Inventor
Bennink Herman Jan Ti Coelingh
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Application granted granted Critical
Publication of DK1556058T3 publication Critical patent/DK1556058T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK03759076T 2002-10-23 2003-10-23 Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi DK1556058T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02079414 2002-10-23
PCT/NL2003/000718 WO2004037269A1 (en) 2002-10-23 2003-10-23 Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy

Publications (1)

Publication Number Publication Date
DK1556058T3 true DK1556058T3 (da) 2008-03-03

Family

ID=32116285

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03759076T DK1556058T3 (da) 2002-10-23 2003-10-23 Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi

Country Status (13)

Country Link
US (2) US8987240B2 (da)
EP (1) EP1556058B1 (da)
CN (1) CN100528167C (da)
AT (1) ATE380552T1 (da)
AU (1) AU2003274823A1 (da)
CA (1) CA2503549C (da)
CY (1) CY1107862T1 (da)
DE (1) DE60318092T2 (da)
DK (1) DK1556058T3 (da)
ES (1) ES2298570T3 (da)
PT (1) PT1556058E (da)
SI (1) SI1556058T1 (da)
WO (1) WO2004037269A1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1526856T1 (sl) 2002-07-12 2008-04-30 Pantarhei Bioscience Bv Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
WO2008024484A1 (en) * 2006-08-25 2008-02-28 Cougar Biotechnology, Inc. Methods and compositions for treating cancer
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
CA2691654C (en) 2007-06-21 2016-06-07 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
MX342537B (es) 2011-06-01 2016-10-04 Estetra Sprl Proceso para la produccion de intermediarios de estetrol.
KR101994805B1 (ko) 2011-06-01 2019-07-01 에스테트라 에스.피.알.엘. 에스테트롤 중간체의 제조 방법
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US20130123222A1 (en) * 2011-11-10 2013-05-16 Sri International, Inc. Synergistic Anti-Cancer Activity of SR16388 with Anti-Mitotic Drugs
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
WO2016203044A1 (en) * 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
CU24523B1 (es) 2015-06-18 2021-06-08 Estetra Sprl Unidad de dosificación orodispersable que contiene un componente estetrol
SI3310345T1 (sl) 2015-06-18 2021-05-31 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
CN116077455A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3031705A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Treatment of prostate cancer with niraparib
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
RU2758386C2 (ru) * 2017-08-01 2021-10-28 Фанд Са Новая вспомогательная терапия для применения в способе лечения рака простаты
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
DE2336433A1 (de) 1973-07-13 1975-04-03 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2336434A1 (de) 1973-07-13 1975-04-17 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
DE2426779A1 (de) 1974-05-31 1975-12-18 Schering Ag 1.3-oxygenierte 8 alpha-oestratriene
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5043331A (en) 1989-06-15 1991-08-27 Orion-Yhtyma Oy Treatment of postmenopausal disorders
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JPH04235171A (ja) 1990-07-26 1992-08-24 Sumitomo Chem Co Ltd スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤
US5063507A (en) * 1990-09-14 1991-11-05 Plains Cotton Cooperative Association Goods database employing electronic title or documentary-type title
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5162117A (en) 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
WO1996003929A1 (en) 1994-08-04 1996-02-15 Biex, Inc. Method for prediction of premature delivery using estetrol (e4) as an indicator
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
EP0994718B1 (en) 1997-06-20 2005-08-17 Akzo Nobel N.V. Gonadotropin releasing hormone antagonist
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AU5137900A (en) 1999-05-28 2000-12-18 University Of Cincinnati, The Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use
WO2001030356A1 (fr) 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
AU773067B2 (en) 1999-11-01 2004-05-13 Torcan Chemical Ltd. Production of polymorphic forms I and II of finasteride by complexation with group I or II metal salts
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
EP1286664B1 (en) 2000-05-12 2007-07-25 Oregon Health and Science University Combination of low dose estrogen and immunotherapeutic agent for treating immune diseases
CA2462081A1 (en) * 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
AU2002240949A1 (en) * 2001-03-21 2002-10-03 Schering Aktiengesellschaft Pharmaceutical combined preparations containing aromatase inhibitors and substances having an estrogen effect in addition to the use thereof for producing a medicament for estrogen-replacement-therapy
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1293210B1 (en) 2001-05-23 2003-11-19 Pantarhei Bioscience B.V. Means and method for hormonal contraception
ATE350041T1 (de) * 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
CA2448273C (en) 2001-05-23 2010-06-29 Christian Franz Holinka Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
US20040198707A1 (en) 2001-05-23 2004-10-07 Agatha Antonia Magdalena Van Beek Means and method for hormonal contraception
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof
US8987240B2 (en) 2002-10-23 2015-03-24 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy

Also Published As

Publication number Publication date
AU2003274823A1 (en) 2004-05-13
CA2503549A1 (en) 2004-05-06
EP1556058A1 (en) 2005-07-27
CN1732007A (zh) 2006-02-08
CN100528167C (zh) 2009-08-19
EP1556058B1 (en) 2007-12-12
SI1556058T1 (sl) 2008-02-29
CY1107862T1 (el) 2013-06-19
ATE380552T1 (de) 2007-12-15
US20150150887A1 (en) 2015-06-04
WO2004037269A1 (en) 2004-05-06
CA2503549C (en) 2012-07-10
PT1556058E (pt) 2008-03-20
ES2298570T3 (es) 2008-05-16
DE60318092D1 (de) 2008-01-24
US8987240B2 (en) 2015-03-24
US20060247221A1 (en) 2006-11-02
DE60318092T2 (de) 2008-11-27
US9561238B2 (en) 2017-02-07

Similar Documents

Publication Publication Date Title
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
IL258880A (en) Compounds of diarylhydantoin
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
NO20075849L (no) Fremgangsmater og preparater til behandling eller forebygging av kreft
SG170809A1 (en) Diarylthiohydantoin compounds
ATE538215T1 (de) Expressionsprofil von prostatakarzinom
RS48804A (en) Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
MXPA05000781A (es) Compuesto antitumor y usos terapeuticos del mismo.
ATE413180T1 (de) Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs
BR0208447A (pt) Inibidores de cinase dependente de ciclina como agente anticâncer
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
ZA200500908B (en) Ruthenium anticancer complexes
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
WO2003106384A3 (en) NOVEL BORIC CHALCONE DERIVATIVES AND USES THEREOF
YU21404A (sh) Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
ATE344670T1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
EA200200313A1 (ru) Применение доцетаксела для лечения печеночно-клеточного рака
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AR024907A1 (es) Uso de inhibidores de la produccion y/o accion de la il-18 y composiciones farmaceuticas formuladas con dichos inhibidores para el tratamiento demetastasis de tumores.
MXPA03002494A (es) Metodo para reducir toxicidad de quimio terapias combinadas.
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof
LV15503A (lv) 2H-selenofēn[3,2-h]hromēni izmantošanai vēža profilaksē un ārstēšanā